In this study, dogs with PD-L1-positive cancers were selectively enrolled in the trial because, in a human clinical trial of anti-PD-1 mAb, 36% of patients with PD-L1-positive cancers responded to the treatment, whereas none with PD-L1-negative cancers had an objective response5. Here, CD274 is linked to cancer.